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The  Malaria  Vaccine  Technology  Roadmap  calls  for a 2015 landmark  goal  of  a ﬁrst-generation  malaria  vac-
cine that  has  protective  efﬁcacy  against  severe  disease  and  death,  lasting  longer  than  one  year.  This  review
focuses  on  product  development  efforts  over  the  last  ﬁve  years  of  RTS,S,  a  pre-erythrocytic,  recombinant
subunit,  adjuvanted,  candidate  malaria  vaccine  designed  with  this goal  of  a ﬁrst-generation  malaria  vac-
cine in  mind.  RTS,S  recently  completed  a successful  pivotal  Phase  III safety,  efﬁcacy  and  immunogenicity
study.  Although  vaccine  efﬁcacy  was  found  to be  modest,  a substantial  number  of cases  of  clinical malariaepatitis B virus surface antigen
were  averted  over a 3–4  years  period,  particularly  in  settings  of  signiﬁcant  disease  burden.  European  reg-
ulators  have  subsequently  adopted  a  positive  opinion  under  the  Article  58  procedure  for  an  indication  of
active  immunization  of children  aged 6  weeks  up  to 17  months  against  malaria  caused  by  Plasmodium  fal-
ciparum  and  against  hepatitis  B. Further  evaluations  of  the  beneﬁt,  risk,  feasibility  and cost-effectiveness
of RTS,S  are  now  anticipated  through  policy  and  ﬁnancing  reviews  at the  global  and  national  levels.
©  2015  Published  by Elsevier  Ltd.  This  is  an  open  access  article  under  the CC BY  license. Introduction
RTS,S, a subunit malaria vaccine candidate, has now reached the
cientiﬁc and regulatory milestone of a positive scientiﬁc opin-
on from European regulators for the prevention of malaria in
oung children in sub-Saharan Africa and continues to progress
oward potentially being the ﬁrst malaria vaccine deployed against
 human parasite. RTS,S is comprised of a liposome-based adjuvant
AS01) and hepatitis B virus surface antigen (HBsAg) virus-like par-
icles incorporating a portion of the Plasmodium falciparum-derived
ircumsporozoite protein (CSP) genetically fused to HBsAg. The
ndication is for active immunization of children aged 6 weeks up
Abbreviations: CHMP, Committee for Medicinal Products for Human Use; CSP,
ircumsporozoite protein; EMA, European Medicines Agency; GFATM, Global Fund
o  Fight Aids, Tuberculosis and Malaria; HBsAg, hepatitis B virus surface antigen;
TT,  intention-to-treat; JTEG, Joint Technical Expert Group; MPAC, Malaria Policy
dvisory Committee; MPL, monophosphoryl lipid A; MVTRM, Malaria Vaccine Tech-
ology Roadmap; PAP, post-approval program; SAGE, Strategic Advisory Group of
xperts; TSP, Thrombospondin-like type I repeat domain; VE, vaccine efﬁcacy; VIS,
accine Investment Strategy; WRAIR, Walter Reed Army Institute of Research; WHO,
orld Health Organization.
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to 17 months against malaria caused by P. falciparum and against
hepatitis B. If approved by national regulatory authorities and rec-
ommended by policy makers in countries of use, development of
RTS,S will have taken more than 30 years (see Fig. 1). For a summary
of the major milestones achieved during the ﬁrst two  dozen years
of RTS,S development, the reader is referred to reviews published
in 2010 [1,2]. The present review focuses on product develop-
ment efforts and the associated scientiﬁc literature over the last
half decade, particularly the Phase III program, the regulatory and
anticipated policy and ﬁnancing pathways, and the planned post-
approval program/Phase IV studies.
But ﬁrst, a recapitulation of the rationale for development of
RTS,S in the context of the Malaria Vaccine Technology Roadmap
developed by World Health Organization (WHO) in consultation
with the Scientiﬁc & Public Health Malaria Community [3,4], is
provided.
2. RTS,S and the Malaria Vaccine Technology Roadmap
2015 Landmark Goal
The Malaria Vaccine Technology Roadmap (MVTRM) was  origi-
nally launched in 2006 and focused on the urgent need for vaccines
to alleviate the ongoing severe disease and death due to malaria.
As such, the priority for the global malaria vaccine development
efforts was on P. falciparum,  children under 5 years of age, and sub-
Saharan Africa and other highly endemic regions. Largely driven by
Y license (http://creativecommons.org/licenses/by/4.0/).
7426 D.C. Kaslow, S. Biernaux / Vaccine 33 (2015) 7425–7432
Fig. 1. The timeline for development of RTS,S through 2015 spans 30 years. The effort by GlaxoSmithKline (GSK) can be traced back to a collaboration with Walter Reed Army
Institute  of Research (WRAIR) initiated in 1984. GSK and the PATH Malaria Vaccine Initiative (MVI) partnership was initiated in 2001. Proof-of-concept (PoC) was established
in  2004 and the pivotal Phase III trial was initiated in 2009 (reviewed in [1]) and completed in 2014 [34]. GSK submitted a regulatory application to the European Medicines
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6].
he progress of early clinical development of RTS,S, the MVTRM set
he following landmark goal: “By 2015, develop and license a ﬁrst-
eneration malaria vaccine that has a protective efﬁcacy of more
han 50 percent against severe disease and death and lasts longer
han one year” [3].
The shared vision and strategic goals of the MVTRM were
xpanded in 2013 to include development of vaccines against Plas-
odium vivax and development of malaria vaccines that reduce
ransmission of the parasite [4]. This expansion was  driven by
arked changes in malaria epidemiology associated with the scale-
p of malaria control measures and the resultant reductions in
alaria parasite transmission, a shift in peak age of clinical malaria
o older age groups, and a decline in malaria-related deaths, cou-
led with substantial changes in the malaria research agenda. As
he focus of the RTS,S development program was on the pediatric
ndication to prevent clinical malaria, the contribution of RTS,S to
he strategic goal of developing vaccines that interrupt malaria
arasite transmission (also known as VIMTs) has been largely unex-
lored to date, other than some recent preliminary ﬁndings that
uggest that serum from RTS,S-vaccinated individuals does not
nhibit sporogony in mosquitoes [5]. That said, the original 2015
andmark, which captures the goal of a ﬁrst-generation malaria vac-
ine, remains unchanged in the updated MVTRM [4]. In that regard,
n 23 July 2015, the Committee for Medicinal Products for Human
se (CHMP) adopted a positive opinion in accordance with the
uropean Medicines Agency (EMA) Article 58 procedure, recom-
ending the granting of a marketing authorization for RTS,S for an
ndication of active immunization of children aged 6 weeks up to
7 months against malaria caused by Plasmodium falciparum and
gainst hepatitis B [6].
. Circumsporozoite protein and RTS,S
The sporozoite plays a central role in the parasite life cycle, from
he maturing Plasmodium oocyst in the midgut of the deﬁnitive
ost to initial infection of the intermediate host. In the case of P.
alciparum, sporozoites are transmitted to the intermediate human
ost through the bites of the deﬁnitive female Anopheles mosquitoMedicinal Products for Human Use (CHMP) adopted a positive opinion in July 2015
hosts having parasite-infected salivary glands. Only a fraction of the
sporozoites in the mosquito salivary glands are injected into the cir-
culation and ultimately infect hepatocytes in susceptible humans.
Because the parasite endures a signiﬁcant numerical bottleneck as
it is transmitted between hosts, it is thought the parasite is most
vulnerable to immune attack as it cycles between the deﬁnitive
and intermediate hosts [7]. That protective immunity able to block
transmission of the parasite as it passes through these numerical
bottlenecks is never acquired [8], despite repeated infections, pro-
vides an opportunity to induce novel immune responses through
active immunization [9].
The circumsporozoite protein (CSP), which is the major surface
protein of Plasmodium ssp. sporozoites, forms a dense coat on the
parasite’s surface and has been proposed to contribute to several
critical roles as the parasites develops within the female mosquito
and infects the mammalian host [10]. Although the primary amino
acid sequences of CSPs differ between Plasmodium ssp., the basic
architectures are similar (Fig. 2): a N-terminus that encodes a sig-
nal peptide sequence, binds heparin sulfate proteoglycans (Region
I), and contains a conserved ﬁve amino acid (KLKQP) proteolytic
cleavage site sequence and Pexel motifs [11]; a middle third that
consists of tandem, species-speciﬁc amino acid repeats that are
immunodominant B-cell epitopes recognized by the neutralizing
antibodies [12] and contributes to sporozoite development in the
mosquito [13]; and a C-terminus that contains a thrombospondin-
like type I repeat domain (TSP) with cell adhesion properties
(Region II), a canonical glycosylphosphatidylinositol (GPI) anchor
addition sequence, and three known T cell epitopes—a highly vari-
able CD4+ T-cell epitope before the TSP, a highly variable CD8+ T-cell
epitope within the TSP, and a “promiscuous” CD4+ T-cell epitope
whose structure is conserved among all parasite isolates [14].
RTS,S contains 189 amino acids from CSP (NF54 199-387aa),
including the last 18 NANP repeats and the C-terminus exclusive
of the GPI anchor addition sequence. Approximately 25% of the
Hepatitis B virus surface antigen (HBsAg) monomers in RTS,S parti-
cles are genetically fused to the truncated CSP and serve as protein
carriers. Despite self-assembly into HBsAg virus-like particles, non-
adjuvant RTS,S is weakly immunogenic and requires an adjuvant
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Fig. 2. Graphical depiction of circumsporozoite (CSP) and RTS,S structures. CSP comprises an N-terminal region containing a signal peptide sequence and Region I that binds
heparin  sulfate proteoglycans and has embedded within it a conserved ﬁve amino acid (KLKQP) proteolytic cleavage site sequence; a central region containing four-amino-
acid  (NANP/NVDP) repeats; and a C-terminal region containing Region II [a thrombospondin (TSP)-like domain] and a canonical glycosylphosphatidylinositol (GPI) anchor
addition sequence. The region of the CSP included in the RTS,S vaccine includes the last 18 NANP repeats and C-terminus exclusive of the GPI anchor addition sequence.
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bepatitis B virus surface antigen (HBsAg) monomers self-assemble into virus-like p
he  truncated CSP and serve as protein carriers. The CSP fragment in RTS,S contain
omain (TH2R), a highly variable CD8+ T-cell epitope within the TSP-like domain (T
o improve the magnitude and duration of the immune responses
o CSP [15]. The Adjuvant System selected [15], AS01, consists of
wo immunostimulants, 3-O-desacyl-4′-monophosphoryl lipid A
MPL) and QS-21 Stimulon® Adjuvant (QS-21), in a liposome for-
ulation. Recent studies suggest that one mechanism of action of
S01 is to transiently stimulate the innate immune system and acti-
ate a high number of efﬁcient antigen-presenting dendritic cells
n the draining lymph nodes [16]. Also recently published are a
epeated dose toxicity study after four administrations of RTS,S at
wo-week intervals in New Zealand white rabbits. As expected an
cute inﬂammatory reaction was observed at the injection sites;
owever, all affected parameters returned to normal within 28
ays after the last injection, indicating full recovery, and no local or
ystemic toxicities were observed [17].
In the context of RTS,S, the absence of the N-terminal region and
he genetic diversity of CSP are worth noting. Immune responses to
he CSP N-terminal region which contains two functional domains
ave been identiﬁed as potential targets for protective antibod-
es [18]. Whether antibodies speciﬁcally directed at the highly
onserved Region I of CSP inhibit parasite binding and/or proteo-
ytic cleavage, and more importantly confer protective immunity
emains to be deﬁnitively established. Whereas the N-terminal
egion of the CSP appears to have limited genetic diversity, the
entral repeat and C-terminal regions are known to be natu-
ally polymorphic, as recently conﬁrmed in Mali [19] and Madhya
radesh, India, where malaria is endemic in a population not pre-
iously exposed to RTS,S [20]. The validation of Region I as a target
f protective immunity may  become important in addressing any
ssues of genetic diversity associated with the more polymorphic
-terminal portion of CSP.
To evaluate CSP genetic diversity in populations administered
TS,S, an ancillary study to the pivotal Phase III trial of RTS,S
described below) was developed to genotype parasites from the
accine trial [21]. Approximately 6,000 samples were drawn, rep-
esenting both enrolled age categories, severe disease cases, ﬁrst
linical episodes, and cross-sectional parasite-positive samples
ollected during study month 20. Parasite variants that infect vac-
inated subjects will be evaluated for known T cell epitope (Th2R,
h3R, CS.T3) haplotypes, as well as differences in B cell epitope
NANP) repeat count distributions within the central repeat region
f CSP. Whether administration of RTS,S is associated with a change
n parasite genetic diversity (within and outside the csp locus) will
e evaluated by enumerating the parasite genotypes to determines and approximately 25% of the HBsAg monomers in RTS,S are genetically fused to
e known T-cell epitopes: a highly variable CD4+ T-cell epitope before the TSP-like
 and a conserved “universal” CD4+ T cell epitope (CS.T3) at the C-terminus.
if the vaccine is limiting the complexity of infection (COI) instead
of selecting for particular parasite variants in the RTS,S vaccinated
population. The goal of this study is to determine if RTS,S selects
speciﬁc parasite variants or alters the number of parasite types
within a vaccinated subject, and to gain a better understanding of
the mechanism of action of the RTS,S [21].
4. Phase III program
The cornerstone of the Phase III program was a pivotal efﬁcacy
and safety trial, MALARIA-055 (NCT00866619) [22,23]), conducted
by the RTS,S Clinical Trials Partnership at 11 clinical trial sites in
seven African countries (one site in Burkina Faso, Gabon, Malawi
and Mozambique; two  sites in Ghana and Tanzania; and, three
sites in Kenya). The trial started in May  2009, enrolled 15,459
infants and young children, concluded in January 2014, and the
results summary through study end posted in January 2015 [23].
This double-blind, individually randomized, controlled, three-arm
trial, in which participants received either three doses of RTS,S
one month apart, followed by a booster dose 18 months later;
three doses of RTS,S followed by a comparator (or ‘control’)
vaccine at the time of booster vaccination; or only control vac-
cines throughout, had two age categories: young children aged
5–17 months and infants aged 6–12 weeks at the time of enroll-
ment. The younger age category was aligned with the infant cohort
targeted for co-administration with routine Expanded Program of
Immunization oral polio and parenteral DTP-containing vaccines.
The details of the trial, designed in consultation with appropriate
regulatory authorities and the World Health Organization (WHO),
have been published [24–27], as have some key learnings from
community engagement during the conduct of the trial [28]. Other
trials in the Phase III program were conducted to further assess
RTS,S in co-administration with other routinely administered vac-
cines, to assess its safety and efﬁcacy in HIV-infected infants and
young children, and to document lot-to-lot consistency of vaccine
manufacturing [29,30].
The pivotal Phase III trial was  conducted in two phases: a double-
blind phase from Month 0–32 [31–33]; and, an extension phase
from Month 33 to study end [34]. The primary aim of the trial was
to assess the efﬁcacy of a three-dose primary vaccination course of
RTS,S against clinical malaria over 12 months follow-up in two age
categories (see above). Secondary aims were to describe the safety
and immunogenicity of RTS,S, to evaluate the efﬁcacy of the vaccine
7  Vacci
c
(
b
a
c
i
m
t
f
a
r
i
9
(
M
e
s
c
ﬁ
l
p
a
l
c
p
t
i
p
−
c
r
t
h
c
t
i
i
a
t
c
s
e
g
f
a
a
v
3
c
c
3
t
c
o
t
a
p
S
(
a
e
a
w428 D.C. Kaslow, S. Biernaux /
andidate against other endpoints of public health importance
e.g., severe malaria and malaria hospitalization), and to evaluate a
ooster dose of RTS,S received at Month 20 with follow-up through
 twelve-month period (Month 32). An additional analysis was
onducted at the end of an extension of the follow-up period,
ncluding an evaluation of safety and efﬁcacy against clinical
alaria, severe malaria and prevalent parasitemia [34].
With respect to the primary aim in the per-protocol popula-
ion of the pivotal Phase III trial, over the Month 2.5 to Month 14
ollow-up period (i.e., 12 months post-dose 3), in the 5–17 months
ge category, the efﬁcacy of RTS,S calculated by negative binomial
egression model against ﬁrst or only episode of malaria meet-
ng the clinical malaria primary case deﬁnition was  55.8% (with
7.5% conﬁdence interval ranging from 50.6% (lower limit) to 60.4%
upper limit), and p-value <0.0001) [23,31]. Over the Month 2.5 to
onth 14 follow-up period, in the 6–12 weeks age category, the
fﬁcacy of RTS,S similarly calculated by negative binomial regres-
ion model against ﬁrst or only episodes of malaria meeting the
linical malaria primary case deﬁnition was 31.3% (with 97.5% con-
dence intervals ranging from 23.6% (lower limit) to 38.3% (upper
imit), and p-value <0.0001) [32].
With respect to the secondary aims of the pivotal Phase III trial
rior to a booster (4th) dose of vaccine (Month 20), several results
re worth noting: (1) vaccine efﬁcacy and immunogenicity were
ower in young infants than in children [32,33]; (2) vaccine efﬁ-
acy waned over time in both age categories (Schoenfeld residuals
 < 0.001) [31–33]; (3) despite modest and waning vaccine efﬁcacy,
he public health impact, reported as the number of cases of clin-
cal malaria, severe malaria and all cause hospitalizations averted
er 1000 persons vaccinated [ranging across sites from 37 to 2365,
1 to 49, and −3 to 131, respectively in the 5–17 month old age
ategory (ITT), and from −10 to 1402, −13 to 37, and −153 to 145,
espectively in the 6–12 week old age category (ITT)] was substan-
ial, particularly, in the older age category and in the context of
igh disease burden—translated to the population at risk of malaria,
ases averted or vaccine preventable disease incidence (VPDI) on
his scale would have a major public health impact [33,35]; (4)
ncreased risk for febrile convulsion within 7 days of administer-
ng RTS,S in children over 5 months of age at time of vaccination;
nd (5) meningitis was reported as a serious adverse event and
he greater number of cases in the RTS,S group compared with the
ontrol vaccine group in the older age category reached statistical
igniﬁcance [33].
With respect to the ﬁnal set of results, which included the
fﬁcacy of a 4th dose of RTS,S, and the efﬁcacy, impact, immuno-
enicity, and safety of RTS,S from ﬁrst vaccination to study end (SE)
or a median follow-up of 38 months in the younger age category
nd 48 months in the older age category, several additional ﬁndings
re noteworthy: (1) a 4th dose appeared to restore and maintain
accine efﬁcacy—VE (ITT) from Month 0 to SE was  36.3% (95% CI
1.8; 40.5) and 32.2% (95% CI 13.7; 46.9) against all episodes of
linical malaria and severe malaria, respectively, in the older age
ategory, and 25.9% (95% CI 19.9; 31.5) and 17.3% (95% CI −9.4;
7.5) against clinical malaria and severe malaria, respectively, in
he younger age category; (2) without a booster, VE (ITT) against
linical malaria continued to wane in both age categories and, in the
lder age category, severe malaria VE became non-signiﬁcant over
he entire study period (VE Month 0–SE = 1.1%, 95% CI −23.0; 20.5)
nd, in fact, the comparative incidence of severe malaria in the time
eriod from Month 21 to SE was signiﬁcantly higher [VE Month 21-
E = −41.0% (95% CI −98.5; −0.8); p = 0.04) than the control group;
3) despite waning efﬁcacy, the number of cases of clinical malaria
verted continued to accumulate in the older and younger age cat-
gories that were administered a 4th dose of RTS,S, reaching an
verage of 1774 and 980 per 1000 children vaccinated, respectively,
ith impact greater in sites with higher malaria burden (Fig. 3);ne 33 (2015) 7425–7432
(4) while administration of a booster dose of RTS,S led to an
increase in anti-circumsporozoite geometric mean titers in both
young infants and children, the titers after the booster was  lower
than concentrations after the primary course and the booster effect
was only transitory; (5) the frequency of SAEs overall was balanced
between groups; however, in the older age category meningitis was
reported as an SAE during the entire study period in 11, 10 and one
child in the four RTS,S dose, three RTS,S dose and control groups,
respectively, while, in contrast, no imbalance in cases of meningi-
tis was noted in the younger age category; and, (6) the incidence of
generalized convulsive seizures within seven days of RTS,S booster
was observed at a higher rate than controls in both the younger
and older age categories (2.2 and 2.5/1000 doses, respectively) [34].
Based on the temporal association and biological plausibility, it was
concluded that there was  a reasonable possibility of causal rela-
tionship between RTS,S and the occurrence of febrile convulsions
within 7 days post-vaccination [34].
A cautionary note: the detailed study analyses contain data from
multiple protocol-speciﬁed and subsequent data analysis plan-
speciﬁed time points, generating hundreds of comparisons and
creating the opportunity for unexpected associations to emerge by
chance. Similarly, the high standard of care provided to all trial par-
ticipants may  have limited the ability of this trial to detect an impact
on more severe outcomes and mortality. With the former caveat in
mind and despite a comprehensive analysis, no obvious explana-
tion for the meningitis observation has been found, and while a
temporal relationship to vaccination is lacking and the biological
plausibility is low, a causal relationship cannot be conﬁrmed or
excluded at this point.
Beyond those highlighted above, additional results of extensive
analyses of secondary, tertiary and exploratory aims of the trial,
can be found in the published literature [31–34] and on the open
access GSK clinical study register [23]. With respect to protective
immune responses, much is still incompletely understood despite
numerous recent analyses [36–40]. While antibody levels and to a
lesser extend cell mediated immune responses, have been shown
to associate with protection against malaria infection, a deﬁnitive
correlate of protection remains elusive.
Table 1 summarizes on-going clinical trials of RTS,S in support
of the pediatric indication. A more comprehensive summary of list
of trials conducted and results published since 2010 can be found
in materials reviewed by WHO  advisory bodies (see below) in 2013
[30].
5. Regulatory, policy, and ﬁnancing pathway
As an initial step in the policy and regulatory process, GSK sub-
mitted a regulatory application to EMA  in June 2014 [41]. The RTS,S
regulatory application was reviewed under the Article 58 proce-
dure, which allows the EMA  to assess the quality, safety and efﬁcacy
of a product intended exclusively for use outside the European
Union (EU) but which is manufactured in a EU member state, to
address a disease recognized by the World Health Organization
(WHO) as of major public health interest [42]. This assessment
was done by the EMA  in collaboration with the WHO  and non-
EU regulators, and requires products to meet the same standards
as a vaccine intended for use in the EU. Under the Article 58 pro-
cedure, the CHMP performed a scientiﬁc evaluation of RTS,S and
in July 2015 issued “a European scientiﬁc opinion”, adopting a
positive opinion and recommending the granting of a marketing
authorization for active immunization of children aged 6 weeks up
to 17 months against malaria caused by P. falciparum and against
hepatitis B, noting that use should be based on ofﬁcial recommen-
dations considering P. falciparum malaria epidemiology in different
geographical areas. It is important to emphasize that a positive
D.C. Kaslow, S. Biernaux / Vaccine 33 (2015) 7425–7432 7429
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(ig. 3. Vaccine efﬁcacy and impact against clinical malaria through study end (Stud
hat  received four doses (R3R) of RTS,S and bar graphs of number of cases averted
opulation of children age 5–17 months (Panel A) and infants age 6–12 weeks (Pan
pinion is not licensure or registration in the EU, but provides a sci-
ntiﬁc opinion that African national regulatory authorities may  use
n their own regulatory review processes as they consider licensure
nd registration in their jurisdictions.
The positive opinion adopted by CHMP also plays a critical role
n decision making by WHO  normative bodies. The technical group
dvising WHO  on Phase 3 trials of malaria vaccines is the Joint Tech-
ical Expert Group (JTEG) on Malaria Vaccines, convened by the
mmunization, Vaccines, and Biologicals Department (IVBD) and
he Global Malaria Program (GMP) [43], and reporting jointly to
trategic Advisory Group of Experts (SAGE) on immunization and
he Malaria Policy Advisory Committee (MPAC) [42,44]. Based on
he positive opinion adopted by CHMP, JTEG’s evaluation of RTS,S
ill now be considered jointly by SAGE and MPAC who  will advise
HO  on recommendation(s) for use, anticipated in the last quar-
er of 2015 [44]. WHO  will also consider RTS,S for prequaliﬁcation
PQ), a process “intended to ensure that a speciﬁc vaccine from
 speciﬁc manufacturer meets international standards of quality,
afety and efﬁcacy and is appropriate for the target population. Only
HO  prequaliﬁed vaccines can be supplied to countries through
N agencies” [43].
Another critical step after WHO  recommendation and PQ wille decisions by various international ﬁnancing organizations and
ublic–private partnerships, including Gavi—the Vaccine Alliance
Gavi), and the Global Fund to Fight Aids, Tuberculosis and Malaria
GFATM), to open country support windows for public ﬁnancing.th 0-SE). Forest plot of vaccine efﬁcacy with 95% conﬁdence intervals for the group
e three dose (R3C) and four dose (R3R) RTS,S groups by site in the intent-to-treat
t ﬁrst vaccination, respectively [33].
In preparation for such a decision, Gavi included a malaria vaccine
in a recent Vaccine Investment Strategy (VIS) review, an evidence-
based prioritization process, undertaken once every ﬁve years, to
identify new vaccines with high priority for inclusion in the Gavi
portfolio [45]. Based on various analyses conducted as part of the
VIS process, including a projection that RTS,S could potentially avert
approximately 1 million future deaths in Africa over 15 years (Fig. 4)
[46], and based on meeting certain pre-speciﬁed conditions [45], it
is anticipated that the Gavi Secretariat will recommend to the Gavi
Board the opening of a country support window, albeit highlight-
ing the importance of coordinating the introduction of a vaccine as
part of integrated malaria control programs and exploring oppor-
tunities for harmonized global procurement strategies with other
international ﬁnancing mechanisms (e.g., GFATM) [45].
Given that all clinical trial data from the ﬁeld are from sub-
Saharan Africa and given the scientiﬁc opinion adopted by CHMP,
it is anticipated that any WHO  recommendation, public ﬁnancing,
national regulatory authority review and national policy recom-
mendations on introduction and use of the vaccine will be restricted
to sub-Saharan Africa, consistent with the ﬁrst landmark goal of the
MVTRM.6. Post-approval program/Phase IV studies
Post-approval studies play an important role in the introduction
and scale-up of vaccines and are critical components of any vaccine
7430 D.C. Kaslow, S. Biernaux / Vaccine 33 (2015) 7425–7432
Table 1
Ongoing/planned RTS,S clinical and epidemiological studies.
Study groups Study and objectives Location Age at enrollment Sample size
Pivotal Ph III efﬁcacy and safety study extension
Same study groups as in the primary
study
• RTS,S/AS01 (3 doses) + RTS,S/AS01
booster dose
• RTS,S/AS01 (3 doses) + control vaccine
•  Control vaccine (3 doses) + control
vaccine
Long-term efﬁcacy, safety and
immunogenicity of RTS,S/AS01 over an
additional 3-year period.
•  Primary endpoint: incidence of
severe malaria.
• Secondary endpoints: clinical
malaria, parasite prevalence and SAEs
of special interest
Tanzania, Kenya,
Burkina Faso
5–17 months or
6–12 weeks
3600
Co-administration Ph IIIb study (Measles, yellow fever and rubella vaccines)
•  RTS,S/AS01 at 6, 7.5 and 9m.  Yellow
fever and measles-rubella vaccines
co-administered at 9 m.
•  RTS,S/AS01 at 6, 7.5 and 9 m,  Yellow
fever and measles-rubella vaccines
staggered at 10m.
• Yellow fever and measles-rubella
vaccines at 9m.
All groups receive vitamin A at 6 m
Non-inferiority of immune response
and safety of the RTS,S/AS01 with or
without co-administration of measles,
yellow fever and rubella vaccines
To be determined 6 months 700
Malaria Transmission Intensity study
6m–4y
5y–19y
20y +
Annual cross-sectional surveys of P.
falciparum parasitemia at peak of
transmission in Ph III pivotal efﬁcacy &
safety study catchment areas, during 4
years.
6 Sub-Saharan
African countries; 8
research centers
6 months to 90
years
6400
Ph  III study on HepB Indication and EPI Integration
•  RTS,S/AS01 + CoAd
(DTPa/Hib + OPV + rotavirus
vaccine) + pneumococcal vaccine
staggered (3 groups—3 lots)
•  RTS,S/AS01 + CoAd
(DTPa/Hib + OPV + pneumococcal
vaccine) + rotavirus staggered (3
groups—3 lots)
•  RTS,S/AS01 + CoAd
(DTPa/Hib + OPV) + rotavirus and
pneumococcal vaccines staggered (3
groups—3 lots)
•  HepB + CoAd
(DTPa/Hib + OPV + pneumococcal
vaccine) + rotavirus vaccine staggered
•  HepB + CoAd
(DTPa/Hib + OPV + rotavirus
vaccine) + pneumococcal vaccine
staggered
Non-inferiority of Hepatitis B immune
response.
Co-administration with 10V S.
pneumonia, non-inferiority of immune
response
Co-administration with rotavirus
vaccine, non-inferiority of immune
response.
Burkina Faso Ghana 8–12 weeks 705
Memory response to the HBs antigen
(booster hepatitis B vaccine given 4
years post primary)
Ph II Schedule optimization study
•  RTS,S/AS01 (≤7d, 10w, 14w)
•  RTS,S/AS01 (≤7d, 10w, 26w)
•  RTS,S/AS01 (6w, 10w, 14w)
• RTS,S/AS01 (6w, 10w, 26w)
• RTS,S/AS01 (6w, 10w, 26w & HepB at
birth)
• RTS,S/AS01 (10w, 14w, 26w)
•  RTS,S/AS01 (14w, 26w, 9m)
•  HepB at birth (control group)
All groups receive: BCG, OPV at birth
DTPw-HepB/Hib, OPV at 6w, 10w, 14w
Exploration of various vaccination
schedules around current EPI visits.
Malawi ≤7d–14w 480
d
d
b
s
t
b
I
t
cMeasles vaccine at 9m
 = days, w = weeks; m = months, y = years of age.
evelopment program, as they address key questions that cannot
e readily addressed in Phase III studies. For example, monitoring
afety and determining effectiveness of vaccines in larger popula-
ions under more “real life” conditions are key data in reﬁning the
eneﬁt-risk proﬁle and optimizing the application of new vaccines.
n the case of RTS,S, the post-approval program is being developed
o meet regulatory commitments as part of the EMA  Article 58 pro-
edure. It can also be used to provide policy and decision-makersin-country, with additional information to assist in deciding on
the use of a new tool in their national vaccine and malaria control
programs.
As it relates to pharmacovigilance and impact, three studies
are currently envisioned. An epidemiology study (EPI-MAL-002),
to “set the baseline” for the incidence of pre-deﬁned diseases
that may  be reported as adverse events following immunization
and for malaria morbidity and mortality. This ﬁrst phase will be
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nig. 4. Gavi projects that RTS,S could potentially avert around 1 million future de
verted (y-axis: cumulative deaths averted over a 15 year period) represents the 
cenario that includes a booster dose [44].
onducted in several countries, and will follow approximately
0,000 children for two years prior to the introduction of RTS,S
n the study communities (this phase will start pre-approval).
his study will be followed by a second phase to be conducted
fter national regulatory approval of RTS,S, such that RTS,S will
e delivered using the immunization system already in place in
he study area. The vaccination study (EPI-MAL-003) will enroll
nother approximately 45,000 children to determine the incidence
f these same pre-deﬁned diseases after immunization with RTS,S.
o leverage and further enhance existing infrastructure, these
wo studies will be conducted at sites that already monitor the
opulation in their catchment area through demographic surveys.
 third study (EPI-MAL-005, a malariometric study), concurrent
o the other two studies, will conduct cross-sectional surveys to
ollect data on the use and coverage of other malaria interventions
nd will track changes in disease burden during the period in
hich EPI-MAL-002 and EPI-MAL-003 are conducted.
In addition to these pharmacovigilance/malaria impact stud-
es (baseline and vaccination phases) and concurrent malaria
ransmission intensity studies, the RTS,S post-approval program
ncludes research in health economics and the piloting of com-
unications materials to support possible introduction. Additional
tudies will be contemplated if deemed needed and feasible.
. Conclusion
RTS,S, a candidate malaria vaccine, has now been success-
ully evaluated in a Phase III program conducted in eight African
ountries and undergone a stringent evaluation by a regulatory
gency. Although vaccine efﬁcacy may  be modest, the number of
ases averted in settings of signiﬁcant disease burden, be it clini-
al malaria, severe malaria or malaria hospitalizations, on the scale
een in MALARIA-055 would have a major public health impact. But
o do so will no doubt require that all available tools be brought to
ear in an optimal way to prevent and treat malaria. In the end, the
eneﬁt, risk, feasibility and cost-effectiveness will be used to deter-
ine the impact of RTS,S. The former has initially been evaluated
hrough EMA’s Article 58 procedure with a positive opinion for ages
 weeks to 17 months, noting that subsequent evaluations are still
eeded by national regulatory authorities. The latter will now be
valuated through policy and ﬁnancing reviews at the global and
ational levels. Africa over 15 years (2015–2030) [46]. The point estimate of 1.1 million deaths
int of the Imperial College and Swiss Tropical Public Health model outputs for a
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